Results 91 to 100 of about 13,113,839 (405)

EO9 (Apaziquone): from the clinic to the laboratory and back again [PDF]

, 2013
EO9 (Apaziquone) is a bioreductive drug that has a chequered history. It underwent clinical trial but failed to show activity in phase II clinical trials when administered i.v.
Aamdal, Adams, Bailey, Bailey, Basu, Bibby, Bibby, Burd, Butler, Cadenas, Ceelen, Choudry, Collard, Connors, Cowan, Cummings, Denny, Dirix, Ernster, Fitzsimmons, Gofrit, Hall, Hargreaves, Hay, Hay, Hay, Hendricksen, Hendricksen, Hendriks, Jain, Loadman, Lu, Maliepaard, Masters, Masters, McKeown, McLeod, Milbank, Minchinton, Oostveen, Pavlidis, Phillips, Phillips, Phillips, Phillips, Phillips, Phillips, Pizao, Plumb, Plumb, Plumb, Puri, Rademakers, Robertson, Robertson, Roed, Schellens, Segura-Aguilar, Siegel, Siegel, Smitskamp-Wilms, Stratford, Sylvester, Tercel, van der Heijden, van der Schoot, van der Schoot, van der Schoot, Vaupel, Vaupel, Walton, Walton, Workman, Workman, Workman, Zappa   +75 more
core   +1 more source

Clinical Medicine and Clinical Trials [PDF]

The Oncologist, 2010
The author discusses the role of clinical trials in clinical medicine.
openaire   +3 more sources

Subpar reporting of pre‐analytical variables in RNA‐focused blood plasma studies

Molecular Oncology, EarlyView.
Pre‐analytical variables strongly influence the analysis of extracellular RNA (cell‐free RNA; exRNA) derived from blood plasma. Their reporting is essential to allow interpretation and replication of results. By evaluating 200 exRNA studies, we pinpoint a lack of reporting pre‐analytical variables associated with blood collection, plasma preparation ...
Céleste Van Der Schueren, Philippe Decruyenaere, Francisco Avila Cobos, Johanna Bult, Jill Deleu, Laudonia Lidia Dipalo, Hetty Hilde Helsmoortel, Eva Hulstaert, Annelien Morlion, Elena Ramos Varas, Kathleen Schoofs, Wim Trypsteen, Eveline Vanden Eynde, Hanne Van Droogenbroeck, Kimberly Verniers, Jo Vandesompele, Anneleen Decock   +16 more
wiley   +1 more source

Using the TIDieR checklist to standardize the description of a functional strength training intervention for the upper limb after stroke [PDF]

, 2016
Background and Purpose: Published reports of intervention in randomized controlled trials are often poorly described. The Template for Intervention Description and Replication (TIDieR) checklist has been recently developed to improve the reporting of ...
Donaldson, Catherine, Hunter, Susan M., Pomeroy, Valerie, Van Vliet, Paulette   +3 more
core   +2 more sources

Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.

Journal of Clinical Oncology, 2017
Purpose Although intensity-modulated radiation therapy (IMRT) is increasingly used to treat locally advanced non-small-cell lung cancer (NSCLC), IMRT and three-dimensional conformal external beam radiation therapy (3D-CRT) have not been compared ...
S. Chun, Chen Hu, H. Choy, R. Komaki, R. Timmerman, S. Schild, J. Bogart, M. Dobelbower, W. Bosch, J. Galvin, V. Kavadi, S. Narayan, P. Iyengar, C. Robinson, R. Wynn, A. Raben, M. Augspurger, R. MacRae, R. Paulus, J. Bradley   +19 more
semanticscholar   +1 more source

Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients

Molecular Oncology, EarlyView.
Cancer‐associated fibroblasts (CAFs) promote cancer growth, invasion (metastasis), and drug resistance. Here, we identified functional and diverse circulating CAFs (cCAFs) in patients with metastatic prostate cancer (mPCa). cCAFs were found in higher numbers and were functional and diverse in mPCa patients versus healthy individuals, suggesting their ...
Richell Booijink, Leon W. M. M. Terstappen, Eshwari Dathathri, Khrystany Isebia, Jaco Kraan, John Martens, Ruchi Bansal   +6 more
wiley   +1 more source

Comparative studies of 2168 plasma proteins measured by two affinity-based platforms in 4000 Chinese adults

Nature Communications
Proteomics offers unique insights into human biology and drug development, but few studies have directly compared the utility of different proteomics platforms.
Baihan Wang, Alfred Pozarickij, Mohsen Mazidi, Neil Wright, Pang Yao, Saredo Said, Andri Iona, Christiana Kartsonaki, Hannah Fry, Kuang Lin, Yiping Chen, Huaidong Du, Daniel Avery, Dan Schmidt-Valle, Canqing Yu, Dianjianyi Sun, Jun Lv, Michael Hill, Liming Li, Derrick A. Bennett, Rory Collins, Robin G. Walters, Robert Clarke, Iona Y. Millwood, Zhengming Chen, On behalf of China Kadoorie Biobank Collaborative Group   +25 more
doaj   +1 more source

Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2): a randomized and double-blind clinical trial

BMC Complementary and Alternative Medicine, 2019
Background Cordyceps is a traditional Chinese herb that produces various biopharmaceutical effects, including immune-enhancing effects. In this study, we prepared a Cordyceps mycelium culture extract (Paecilomyces hepiali, CBG-CS-2) to confirm its ...
Su-Jin Jung, Eun-Soo Jung, Eun-Kyung Choi, Hong-Sig Sin, Ki-Chan Ha, Soo-Wan Chae   +5 more
doaj   +1 more source

Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer’s disease: a randomized phase 1 study

BMC Medicine, 2023
Background AD16 is a Class 1.1 new drug candidate for Alzheimer’s disease (AD), which has demonstrated potential benefits in AD by reducing neuroinflammation in preclinical studies.
Daizhuang Peng, Sumei Xu, Ting Zou, Yahui Wang, Wenjuan Ouyang, Yalan Zhang, Chengmei Dong, Dai Li, Jie Guo, Qiuying Shen, Xiaolei Hu, Wenzhi Zhou, Xiaomin Li, Qun Qin   +13 more
doaj   +1 more source

A general Bayesian approach to design adaptive clinical trials with time-to-event outcomes [PDF]

arXiv, 2023
Clinical trials are an integral component of medical research. Trials require careful design to, for example, maintain the safety of participants, use resources efficiently and allow clinically meaningful conclusions to be drawn. Adaptive clinical trials (i.e.
arxiv